(Reuters) – Inovio Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company’s trial of its COVID-19 vaccine.
The FDA last year put the final-stage trial on hold as it sought more information from the company, including details on a delivery device used to inject genetic material into cells.
Inovio said the FDA’s review was complete, and the agency had provided authorization to proceed with the study.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
